US 11103491
Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer
granted A61KA61K31/443A61K31/4439
Quick answer
US patent 11103491 (Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer) held by Asana BioSciences, LLC expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Asana BioSciences, LLC
- Grant date
- Tue Aug 31 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 12
- CPC classes
- A61K, A61K31/443, A61K31/4439, A61K31/444, A61K31/506